Drug Profile
Research programme: cancer therapeutics - Angiotech/Sanofi
Latest Information Update: 31 Mar 2022
Price :
$50
*
At a glance
- Originator Angiotech Pharmaceuticals; Genzyme Corporation
- Developer Angiotech Pharmaceuticals; Sanofi
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 09 May 2006 Early research in Cancer in USA and Canada (Parenteral)